Levonorgestrel IUD feasible for low-risk, early uterine cancer

Levonorgestrel IUD feasible for low-risk, early uterine cancer

(HealthDay)—A levonorgestrel-releasing intrauterine device (LNG-IUD) is effective in the majority of patients undergoing conservative treatment for low-risk endometrial cancer and complex atypical hyperplasia, according to a case-series study published online Dec. 4 in Obstetrics & Gynecology.

Navdeep Pal, M.B.B.S., M.P.H., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues retrospectively reviewed 46 cases treated with the LNG-IUD for complex atypical or early-grade endometrial cancer from January 2003 to June 2013.

The researchers found that 15 of the 32 evaluable patients at the six-month time point had complex atypical hyperplasia (47 percent), nine had G1 endometrial cancer (28 percent), and eight had grade 2 endometrial cancer (25 percent). At six months, the overall response rate was 75 percent (80 percent in complex atypical hyperplasia, 67 percent in grade 1 endometrial cancer, and 75 percent in grade 2 endometrial cancer). There was a trend toward an association between lack of exogenous progesterone effect in the pathology specimen and nonresponse to the IUD (P = 0.05). In women who did not respond to the IUD, median uterine diameter was 1.3 cm larger (P = 0.04).

"Levonorgestrel-releasing IUD therapy for the of complex atypical hyperplasia or early-grade resulted in return to normal histology in a majority of patients," the authors write.

One author disclosed financial ties to the pharmaceutical industry.


Explore further

Low CA risk for premenopausal abnormal uterine bleeding

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: Obstetrics & Gynecology

Copyright © 2017 HealthDay. All rights reserved.

Citation: Levonorgestrel IUD feasible for low-risk, early uterine cancer (2017, December 20) retrieved 27 October 2020 from https://medicalxpress.com/news/2017-12-levonorgestrel-iud-feasible-low-risk-early.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments